A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

The report forecasted that the Alzheimer's disease market in these countries to grow from $2.4 billion in 2023 to $19.3 ...

A recent study published in Neurology explored whether high doses of nicotinamide, a derivative of vitamin B3, could reduce a ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

It is a familiar activity to everyone, but reminiscence can be highly beneficial for people with Alzheimer’s disease. It can support self-esteem and develop interpersonal skills. This article explains ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Once daily oral administration of blarcamesine meaningfully slowed clinical decline in early Alzheimer’s disease patients, demonstrating a favorable ... oral blarcamesine could represent a novel ...

Once daily oral administration of blarcamesine meaningfully slowed clinical decline in early Alzheimer's disease ... a novel treatment that could be complementary or an alternative to injectable ...

Alzheimer's disease (AD ... with a stabilization of the disease in a proportion of patients with mild AD after 3 years of treatment. Tramiprosate is being investigated in two pivotal 18-month ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...